NCT01482403 - A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Copegus

total daily dose of 1000 mg or 1200 mg for 24 weeks

DRUG

Copegus

total daily dose of 1000 mg or 1200 mg for 48 weeks

DRUG

Pegasys

180 microgram subcutaneous once a week for 24 weeks

DRUG

Pegasys

180 microgram subcutaneous once a week for 48 weeks

DRUG

boceprevir

800 mg three times a day for 24 weeks

DRUG

boceprevir

800 mg three times a day for 48 weeks

DRUG

mericitabine

1000 mg twice daily for 24 weeks

DRUG

mericitabine placebo

DRUG

boceprevir placebo

DRUG

boceprevir

800 mg three times a day for 44 weeks

Trial Locations (24)

13353

Berlin

20099

Hamburg

20121

Milan

30625

Hanover

35033

Rennes

36071

Pontevedra

39008

Santander

46014

Valencia

48202

Detroit

50134

Florence

60637

Chicago

64128

Kansas City

71130

Shreveport

78215

San Antonio

80120

Littleton

80131

Napoli

94010

Créteil

23320-1706

Chesapeake

T2N 4Z6

Calgary

V5Z 1H2

Vancouver

N6A 5A5

London

06202

Nice

00716

Ponce

07010

Palma de Mallorca

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY